Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aggressive infantile embryonal tumors.

Tobey J MacDonald1

  • 1Division of Oncology, Center for Cancer and Blood Disorders, Center for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, DC 20010, USA. tmacdona@cnmc.org

Journal of Child Neurology
|October 28, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

Neuro-oncology·2026
Same author

Data-Driven Feedback Identifies Focused Ultrasound Exposure Regimens for Improved Nanotheranostic Targeting of the Brain.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients.

JCI insight·2025
Same author

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

bioRxiv : the preprint server for biology·2025
Same author

Data-driven feedback augments ultrasound nanotheranostics in brain tumors.

bioRxiv : the preprint server for biology·2025
Same journal

Birmingham, 1963.

Journal of child neurology·2026
Same journal

Hyperintensity on Diffusion-Weighted Imaging in a MELAS Patient Does Not Necessarily Mean Cytotoxic Edema.

Journal of child neurology·2026
Same journal

Neuromuscular Symptoms of <i>ORAI1</i>-Related Immunodeficiency.

Journal of child neurology·2026
Same journal

Symptoms of Obsessive-Compulsive Disorder, Attention-Deficit/Hyperactivity Disorder, and Autism Spectrum Disorder in Children and Adolescents Attending a Headache Outpatient Clinic and School-Based Controls.

Journal of child neurology·2026
Same journal

Acute Encephalopathy From Central Nervous System Hemophagocytic Lymphohistiocytosis (CNS HLH) in X-Linked Lymphoproliferative Disease Type 1 (XLP-1).

Journal of child neurology·2026
Same journal

The Cost of Fear for Pediatric Neurologic Care.

Journal of child neurology·2026
See all related articles

Infantile embryonal brain tumors are aggressive and have poor outcomes. Identifying molecular targets is crucial for developing new treatments for these rare pediatric cancers.

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Molecular Pathology

Background:

  • Embryonal tumors are the most frequent brain tumors in infants under 36 months.
  • These tumors are histologically undifferentiated small, round cell tumors with diverse differentiation patterns.
  • Common types include medulloblastoma, supratentorial primitive neuroectodermal tumor, and atypical teratoid/rhabdoid tumor.

Purpose of the Study:

  • To review the molecular and clinical aspects of the three most common aggressive infantile embryonal brain tumors.
  • To highlight the need for identifying specific molecular targets for prognostic and therapeutic implications.
  • To discuss the unique management strategies for these tumors in infants, considering the avoidance of craniospinal irradiation.

Main Methods:

Related Experiment Videos

  • Literature review focusing on molecular and clinical data of infantile embryonal brain tumors.
  • Analysis of histological characteristics and dissemination patterns.
  • Examination of treatment strategies and outcomes in infants.

    • Main Results:

    • Embryonal tumors share aggressive behavior and a tendency for central nervous system dissemination.
    • Outcomes are consistently poor across all embryonal tumor types in infants.
    • Management is unique in infants due to efforts to minimize treatment-related neurotoxicity.

    Conclusions:

    • Specific molecular targets are crucial for improving prognosis and developing targeted therapies.
    • Further research into the molecular underpinnings of these tumors is essential.
    • Novel therapeutic strategies are needed to improve survival rates for infants with embryonal brain tumors.